Abstract
Purpose. The cytochrome P450 (CYP) enzymes play a critical role in the oxidative metabolism of a variety of endogenous and exogenous compounds, including drugs. Although intermediate CYP metabolites are believed to play a role in carcinogenesis, little is known about tissue-specific CYP expression and the role of local activation in breast carcinogenesis. The goals of this study are to identify CYPs expressed in breast tissue by measuring mRNA levels and to determine whether there are differences in mRNA levels between breast tumors and histologically-normal adjacent breast tissue.
Experimental design. Quantitative reverse-transcriptase polymerase chain reaction (RT-PCR) analysis was used to quantitate mRNA expression levels of 11 CYPs in 29 human breast tumor and non-tumor adjacent tissue pairs. The CYPs examined included: CYP1A1, CYP1A2, CYP1B1, CYP2C8, CYP2C9, CYP2C18, CYP2C19, CYP2D6, CYP2E1, CYP3A4, and CYP3A5.
Results. Only four CYPs were detected in breast tumor or adjacent tissue: CYP1A1, CYP1B1, CYP2C9, CYP3A4. Each of these CYPs was expressed in at least 75% of the samples. Three of these CYPs are involved in estradiol hydroxylation (CYP1A1, 2-OH; CYP1B1, 4-OH; CYP3A4, 2- and 16-OH). CYP2C9 is involved in the conversion of estrone sulfate to the 16-hydroxy sulfate metabolite. Higher levels of CYP1B1 and 3A4 were found more often in non-tumor tissue than in tumor tissue (P < 0.04). CYP1A1 was elevated in non-tumor tissue only among pairs in which the tumor expressed the estrogen receptor (ER+, P < 0.03). All of these results were independent of recorded clinical–pathological covariates.
Conclusions. CYPs involved in estrogen metabolism are expressed in both tumor and non-tumor breast tissue. Local activation of estrogen to potentially reactive metabolites by the CYPs in breast tissue may play a role in initiating and promoting the carcinogenic process.
Similar content being viewed by others
References
Miller JA, Miller EC: Some historical aspects of N-aryl carcinogens and their metabolic activation. Environ Health Perspect 49: 3-12, 1983
Nelson DR, Koymans L, Kamataki T, Stegeman JJ, Feyereisen R, Waxman DJ, Waterman MR, Gotoh O, Coon MJ, Estabrook RW, Gunsalus IC, Nebert DW: P450 Superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics 6: 1-42, 1996
Albin N, Massaad L, Toussaint C, Mathieu MC, Morizet J, Parise O, Gouyette A, Chabot GG: Main drug-metabolizing enzyme systems in human breast tumors and peritumoral tissues. Cancer Res 53: 3541-3546, 1993
Forrester LM, Hayes JD, Millis R, Barnes D, Harris AL, Schlager JJ, Powis G, Wolf CR: Expression of glutathione Stransferases and cytochrome P450 in normal and tumor breast tissue. Carcinogenesis, 11: 2163-2170, 1990
Huang Z, Fasco MJ, Figge HL, Keyomarsi K, Kaminsky LS: Expression of cytochromes P450 in human breast tissue and tumors. Drug Metab Dispos 24: 899-905, 1996
Iscan M, Klaavuniemi T, Coban T, Kapucuoglu N, Pelkonen O, Raunio H: The expression of cytochrome P450 enzymes in human breast tumours and normal breast tissue. Breast Cancer Res Treat 70: 47-54, 2001
Carcillo JA, Parise RA, Romkes-Sparks M: Comparison of the enzyme-linked oligonucleotide sorbent assay to the 32PPCR/ Southern blotting technique in quantitative analysis of human and rat actin mRNA. PCR Methods Appl 3: 292-297, 1994
Shipiro SS, Wilk MB: An analysis of variance test for normality (complete samples). Biometrika 52: 591-611, 1965
Hellmold H, Rylander T, Magnusson M, Reihner E, Warner M, Gustafsson JA: Characterization of cytochrome P450 enzymes in human breast tissue from reduction mammaplasties. J Clin Endocrinol Metab, 83: 886-895, 1998
Slaughter DP, Southwick HW, Smejkal W: Field cancerization in oral stratified squamous epithelium. Cancer 6: 963-968, 1953
Forsti A, Louhelainen J, Soderberg M, Wijkstrom H, Hemminki K: Loss of heterozygosity in tumour-adjacent normal tissue of breast and bladder cancer. Eur J Cancer 37: 1372-1380, 2001
Liehr JG, Fang WF, Sirbasku DA, Ari-Ulubelen A: Carcinogenicity of catechol estrogens in Syrian hamsters. J Steroid Biochem 24: 353-356, 1986
Van Aswegen CH, Purdy RH, Wittliff JL: Binding of 2-hydroxyestradiol and 4-hydroxyestradiol to estrogen receptors in human breast cancers. J Steroid Biochem 32: 485-492, 1989
Barnea ER, MacLusky NJ, Naftolin F: Kinetics of catechol estrogen-estrogen receptor dissociation: a possible factor underlying differences in catechol estrogen biological activity. Steroids 41: 643-656, 1983
Liehr JG, Ricci MJ: 4-hydroxylation of estrogens as a marker of human mammary tumors. Proc Natl Acad Sci 93: 3294-3296, 1996
Liehr JG, Ulubelen AA, Strobel HW: Cytochrome P-450-mediated redox cycling of estrogens. J Biol Chem 261: 16865-16870, 1986
Yager JD, Liehr JG: Molecular mechanisms of estrogen carcinogenesis. Annu Rev Pharmacol Toxicol 36: 203-232, 1996
Hayashi N, Hasegawa K, Komine A, Tanaka Y, McLachlan JA, Barrett JC, Tsutsui T: Estrogen-induced cell transformation and DNA-adduct formation in cultured Syrian hamster embryo cells. Mol Carcinog 16: 149-156, 1996
Cavalieri EL, Stack DE, Devanesan PD, Todorovic R, Dwivedy I, Higginbotham S, Johansson SL, Patil KD, Gross ML, Gooden JK, Ramanathan R, Cerny RL, Rogan EG: Molecular origin of cancer: catechol estrogen-3,4-quinones as endogenous tumor initiators. Proc Natl Acad Sci 94: 10937-10942, 1997
Zhu BT, Conney AH: Functional role of estrogen metabolism in target cells: review and perspectives. Carcinogenesis 19: 1-27, 1998
Fishman J, Martucci C: Biological properties of 16alphahydroxyestrone: implications in estrogen physiology and pathophysiology. J Clin Endocrinol Metab 51: 611-615, 1980
Bradlow HL, Herschcopf RJ, Fishman J: Estradiol 16alphahydroxylation in the mouse correlates with mammary tumor incidence and presence of murne mammary tumor virus: a possible model for the hormonal etiiology of breast cancer in humans. Proc Natl Acad Sci USA 82: 6295-6299, 1985
Ho G, Luo X, Ji C, Foo S, Ng E: Urinary 2/16?-hydroxyestrone ratio: correlation with serum insulinlike growth factor binding protein-3 and a potential biomarker of breast cancer risk. Ann Acad Med Singapore 27: 294-299, 1998
Kabat GC, Chang CJ, Sparano JA, Sepkovic DW, Hu XP, Khalil A, Rosenblatt R, Bradlow HL: Urinary estrogen metabolites and breast cancer: a case-control study. Cancer Epidemiol Biomarkers Prev 6: 505-509, 1997
Schneider J, Kinne D, Fracchia A, Pierce V, Anderson KE, Bradlow HL, Fishman J: Abnormal oxidative metabolism of estradiol in women with breast cancer. Proc Natl Acad Sci 79: 3047-3051, 1982
Zheng W, Dunning L, Jin F, Holtzman J: Urinary estrogen metabolites and breast cancer: a case control study. Cancer Epidemiol Biomarkers Prev 6: 500-504, 1997
Meilahn EN, DeStavola B, Allen DS, Fentiman I, Bradlow HL, Sepkovic DW, Kuller LH: Do urinary estrogen metabolites predict breast cancer? Guernsey III cohort follow-up. Br J Cancer 78: 1250-1255, 1998
Feigelson HS, Henderson BE: Estrogens and breast cancer. Carcinogenesis 17: 2279-2284, 1996
Vandewalle B, Lefebvre J: Opposite effects of estrogen and catechol estrogen on hormone sensitive breast cancer cell growth and differentiation. Mol Cell Endocrinol 6: 239-246, 1989
Lipsett MB, Merriam GR, Kono S, Brandon DD, Pfeiffer DG, Merriam GR: Metabolic clearance of catechol estrogens. In Merriam GR, Lipsett MB (eds) Catechol Estrogens, Raven Press, New York, 1983, pp 105-114
Fotsis T, Zhang Y, Pepper MS, Aldecreutz H, Montesano R, Nawroth PP, Schwelgerer L: The endogenous oestrogen metabolite 2-methoxyoestradiol inhibits angiogenesis and suppresses tumor growth. Nature 368: 237-239, 1994
Emons G, Merriam GR, Pfeiffer D, Loriaux DL, Ball P, Knuppen R. Metabolism of exogenous 4-and 2-hydroxyestradiol in the human male. J Steroid Biochem 28: 499-504, 1987
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Modugno, F., Knoll, C., Kanbour-Shakir, A. et al. A Potential Role for the Estrogen-metabolizing Cytochrome P450 Enzymes in Human Breast Carcinogenesis. Breast Cancer Res Treat 82, 191–197 (2003). https://doi.org/10.1023/B:BREA.0000004376.21491.44
Issue Date:
DOI: https://doi.org/10.1023/B:BREA.0000004376.21491.44